RS65137B1 - Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina sa s konfiguracijom u položaju 4 - Google Patents
Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina sa s konfiguracijom u položaju 4Info
- Publication number
- RS65137B1 RS65137B1 RS20240135A RSP20240135A RS65137B1 RS 65137 B1 RS65137 B1 RS 65137B1 RS 20240135 A RS20240135 A RS 20240135A RS P20240135 A RSP20240135 A RS P20240135A RS 65137 B1 RS65137 B1 RS 65137B1
- Authority
- RS
- Serbia
- Prior art keywords
- pharmaceutical preparation
- solution
- methoxy
- trifluoromethyl
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101680A DE102012101680A1 (de) | 2012-02-29 | 2012-02-29 | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| EP19176985.0A EP3556350B1 (de) | 2012-02-29 | 2013-02-28 | Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat mit s-konfiguration in position 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65137B1 true RS65137B1 (sr) | 2024-02-29 |
Family
ID=47757622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240135A RS65137B1 (sr) | 2012-02-29 | 2013-02-28 | Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina sa s konfiguracijom u položaju 4 |
| RSP20191076 RS59157B1 (sr) | 2012-02-29 | 2013-02-28 | Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP20191076 RS59157B1 (sr) | 2012-02-29 | 2013-02-28 | Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina |
Country Status (37)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| HUE043721T2 (hu) * | 2013-06-19 | 2019-09-30 | Aicuris Anti Infective Cures Gmbh | Amorf letermovir és szilárd gyógyászati készítményei orális adagolásra |
| AU2017274722A1 (en) | 2016-06-03 | 2019-01-17 | Atreya Innovations Private Limited | A device for the detection and reliable capturing of the pulse characteristics |
| PL3592362T3 (pl) | 2017-03-06 | 2025-06-23 | VenatoRx Pharmaceuticals, Inc. | Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania |
| UY39095A (es) * | 2020-02-27 | 2021-09-30 | Aic246 Gmbh & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio |
| UY39099A (es) * | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo |
| CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
| CN115403528B (zh) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN113880776B (zh) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | 一种莱特莫韦中间体的制备方法 |
| AR128035A1 (es) | 2021-12-21 | 2024-03-20 | Aic246 Ag & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio |
| JP2025504136A (ja) * | 2022-02-23 | 2025-02-06 | エルジー・ケム・リミテッド | イソキサゾリン誘導体を含む注射用製剤及びこの製造方法 |
| CN115322157B (zh) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | 来特莫韦中间体化合物及其制备方法和应用 |
| WO2024037485A1 (zh) * | 2022-08-15 | 2024-02-22 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
| CN115677539B (zh) * | 2022-11-01 | 2023-10-24 | 南京工业大学 | 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法 |
| CN119015222B (zh) * | 2024-08-28 | 2025-12-09 | 石家庄四药有限公司 | 一种来特莫韦注射液及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1242699A (en) * | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
| CA1284994C (en) * | 1985-08-05 | 1991-06-18 | Murray Arthur Kaplan | Cephalosporin salts and injectable compositions |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| IT1304190B1 (it) * | 1998-12-18 | 2001-03-08 | Euphar Group Srl | Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche |
| WO2000055153A1 (en) * | 1999-03-17 | 2000-09-21 | Astrazeneca Ab | Amide derivatives |
| WO2001091751A1 (en) * | 2000-05-30 | 2001-12-06 | Novo Nordisk A/S | New pharmaceutical composition and the process for its preparation |
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| EP1689724B1 (en) * | 2003-11-25 | 2011-12-21 | Novartis AG | Quinazolinone compounds as anticancer agents |
| EP1846410B1 (en) * | 2005-02-10 | 2009-01-21 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| US8743287B2 (en) * | 2009-07-24 | 2014-06-03 | Broadcom Corporation | Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction |
-
2012
- 2012-02-29 DE DE102012101680A patent/DE102012101680A1/de not_active Ceased
-
2013
- 2013-02-28 EP EP19176985.0A patent/EP3556350B1/de active Active
- 2013-02-28 PL PL19176985.0T patent/PL3556350T3/pl unknown
- 2013-02-28 ME MEP-2019-219A patent/ME03448B/me unknown
- 2013-02-28 PT PT191769850T patent/PT3556350T/pt unknown
- 2013-02-28 PH PH1/2014/501937A patent/PH12014501937B1/en unknown
- 2013-02-28 DK DK13707000.9T patent/DK2819648T3/da active
- 2013-02-28 PT PT13707000T patent/PT2819648T/pt unknown
- 2013-02-28 HU HUE19176985A patent/HUE065553T2/hu unknown
- 2013-02-28 BR BR112014020946-4A patent/BR112014020946B1/pt active IP Right Grant
- 2013-02-28 AU AU2013224947A patent/AU2013224947B2/en active Active
- 2013-02-28 FI FIEP19176985.0T patent/FI3556350T3/fi active
- 2013-02-28 SG SG11201405294XA patent/SG11201405294XA/en unknown
- 2013-02-28 ES ES13707000T patent/ES2741698T3/es active Active
- 2013-02-28 MY MYPI2014002461A patent/MY172310A/en unknown
- 2013-02-28 HR HRP20191369 patent/HRP20191369T1/hr unknown
- 2013-02-28 EP EP13707000.9A patent/EP2819648B1/de active Active
- 2013-02-28 WO PCT/EP2013/054114 patent/WO2013127970A1/de not_active Ceased
- 2013-02-28 PL PL13707000T patent/PL2819648T3/pl unknown
- 2013-02-28 LT LTEP19176985.0T patent/LT3556350T/lt unknown
- 2013-02-28 DK DK19176985.0T patent/DK3556350T3/da active
- 2013-02-28 EP EP24150976.9A patent/EP4328218A3/de active Pending
- 2013-02-28 LT LTEP13707000.9T patent/LT2819648T/lt unknown
- 2013-02-28 CN CN201910661203.8A patent/CN110433166A/zh active Pending
- 2013-02-28 US US14/381,290 patent/US10603384B2/en active Active
- 2013-02-28 JP JP2014559233A patent/JP6387486B2/ja active Active
- 2013-02-28 RS RS20240135A patent/RS65137B1/sr unknown
- 2013-02-28 SM SM20190458T patent/SMT201900458T1/it unknown
- 2013-02-28 SI SI201331541T patent/SI2819648T1/sl unknown
- 2013-02-28 KR KR1020147023803A patent/KR102149561B1/ko active Active
- 2013-02-28 HR HRP20240197TT patent/HRP20240197T1/hr unknown
- 2013-02-28 NZ NZ628444A patent/NZ628444A/en unknown
- 2013-02-28 RS RSP20191076 patent/RS59157B1/sr unknown
- 2013-02-28 EA EA201400963A patent/EA026584B1/ru unknown
- 2013-02-28 HU HUE13707000A patent/HUE045949T2/hu unknown
- 2013-02-28 ES ES19176985T patent/ES2972133T3/es active Active
- 2013-02-28 IN IN1892MUN2014 patent/IN2014MN01892A/en unknown
- 2013-02-28 CA CA2865203A patent/CA2865203C/en active Active
- 2013-02-28 MX MX2014010364A patent/MX369666B/es active IP Right Grant
- 2013-02-28 UA UAA201410519A patent/UA111415C2/uk unknown
- 2013-02-28 SM SM20240068T patent/SMT202400068T1/it unknown
- 2013-02-28 SI SI201332077T patent/SI3556350T1/sl unknown
- 2013-02-28 CN CN201380011670.7A patent/CN104144678A/zh active Pending
-
2014
- 2014-08-08 TN TNP2014000345A patent/TN2014000345A1/fr unknown
- 2014-08-13 ZA ZA2014/05949A patent/ZA201405949B/en unknown
- 2014-08-28 IL IL234363A patent/IL234363B/en active IP Right Grant
- 2014-08-28 CO CO14189543A patent/CO7061076A2/es unknown
- 2014-08-29 CL CL2014002306A patent/CL2014002306A1/es unknown
- 2014-09-17 MA MA37360A patent/MA35941B1/fr unknown
-
2019
- 2019-08-20 CY CY20191100885T patent/CY1121910T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS65137B1 (sr) | Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina sa s konfiguracijom u položaju 4 | |
| DK2820001T3 (en) | SODIUM AND CALCIUM SALTS OF A DIHYDROQUINAZOLINE DERIVATIVE AND THEIR USE AS ANTIVIRAL AGENTS | |
| DK2623498T3 (en) | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide | |
| TWI865508B (zh) | Hbv核心蛋白別構調節劑化合物之固體型式 | |
| CN115417834B (zh) | 一类取代苯甲酰哌嗪类化合物及在制备抗基孔肯雅病毒药物中的应用 | |
| HK40107621A (en) | Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative | |
| KR880001751B1 (ko) | 설폰아미드-강화제 용액의 제조방법 | |
| HK40014816B (en) | Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative with s configuration in position 4 | |
| HK40014816A (en) | Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative with s configuration in position 4 | |
| HK1205462B (en) | Pharmaceutical preparation comprising an antiviral dihydroquinazoline derivative |